Inventor · disambiguated record
Hirofumi Jono
Also filed as: JONO HIROFUMI
4 granted patents·7 pending applications·1 citations·filing 2011–2022
57Inventor score
Files withALNYLAM PHARMACEUTICALS INC4KM BIOLOGICS CO LTD3ANDO YUKIO2HIROTSU BIO SCIENCE INC1NATION UNIV CORPORATION KUMAMOTO UNIV1
Top patents by PatentIndex Score
11 records- 0173US2020199592A1siRNA Therapy for Transthyretin (TTR) Related Ocular AmyloidosisALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 0267US10604562B2Anti-transthyretin humanized antibodyKM BIOLOGICS CO LTD·Filed 2015·Granted Mar 31, 2020·1 cites·16 claims
- 0362US2023340473A1Sirna therapy for transthyretin (ttr) related ocular amyloidosisALNYLAM PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 0460US11186630B2Anti-transthyretin human antibodyKM BIOLOGICS CO LTD·Filed 2020·Granted Nov 30, 2021·0 cites·4 claims
- 0559US2018171332A1siRNA Therapy for Transthyretin (TTR) Related Ocular AmyloidosisALNYLAM PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0656US2017096663A1siRNA Therapy for Transthyretin (TTR) Related Ocular AmyloidosisALNYLAM PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0753US2013281510A1siRNA Therapy for Transthyretin (TTR) Related Ocular AmyloidosisANDO YUKIO·Filed 2011·Application pending·0 cites
- 0852US2016076029A1siRNA Therapy for Transthyretin (TTR) Related Ocular AmyloidosisANDO YUKIO·Filed 2015·Application pending·0 cites
- 0950US11725226B2Method for detecting kidney cancerHIROTSU BIO SCIENCE INC·Filed 2018·Granted Aug 15, 2023·0 cites·8 claims
- 1041US10597440B2Anti-transthyretin human antibodyKM BIOLOGICS CO LTD·Filed 2015·Granted Mar 24, 2020·0 cites·19 claims
- 1133US2018264025A1Novel amyloid fibril formation inhibitorNATION UNIV CORPORATION KUMAMOTO UNIV·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hirofumi Jono files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →